Primary Biliary Cholangitis – Pipeline Review, H1 2020: Allwegan Plc, GenKyoTex SA, Kowa Co Ltd & PRISM Pharma Co Ltd – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cholangitis – Pipeline Review, H1 2020, provides an overview of the Primary Biliary Cholangitis (Gastrointestinal) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cholangitis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Primary Biliary Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 2, 9, 4, 1, 1 and 3 respectively.

Primary Biliary Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cholangitis (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Primary Biliary Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Primary Biliary Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Primary Biliary Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cholangitis (Gastrointestinal)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cholangitis (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Primary Biliary Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Overview
• Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Therapeutics Development
• Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Therapeutics Assessment
• Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Companies Involved in Therapeutics Development
• Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Drug Profiles
• Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Dormant Projects
• Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Discontinued Products
• Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Product Development Milestones
• Appendix

Companies Mentioned

• Abcuro Inc
• Allergan Plc
• Cadila Healthcare Ltd
• Calliditas Therapeutics AB
• Chia Tai Tianqing Pharmaceutical Group Co Ltd.
• Dr. Falk Pharma GmbH
• Eli Lilly and Co
• Enanta Pharmaceuticals Inc
• Genfit SA
• GenKyoTex SA
• Gilead Sciences Inc
• GlaxoSmithKline Plc
• Kowa Co Ltd
• MYR GmbH
• NGM Biopharmaceuticals Inc
• Novartis AG
• PRISM Pharma Co Ltd
• Suzhou Zelgen Biopharmaceutical Co Ltd
• Tiziana Life Sciences Plc
• Virobay Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lr832u

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900